Clinical Trial Update: Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome [Phase 2]

View source ↗

Summary

Phase 2 safety study of HemaMax (rHuIL-12) for acute radiation syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Syndrome Due to Acute Radiation Syndrome

Drugs mentioned

• HemaMax (recombinant human interleukin-12)

Snippet

Sponsor: Neumedicines Inc. | Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome | Phase 2 | Status: COMPLETED